Twitter Linkedin

Arch Biopartners

Arch Biopartners is a late-stage clinical trial company focused on preventing inflammation and acute organ injury.

Arch is developing a platform of novel therapeutic drugs, led by LSALT peptide (Metablok), that are:
  • designed to inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP1) pathway and,
  • relevant for common organ injuries and diseases where organ inflammation is an unmet problem with no effective treatments in the market today.
ABOUT LSALT PEPTIDE

Following our scientists’ identification of DPEP1 as an adhesion receptor in the lungs, kidneys and liver and their discovery that DPEP1 was shown to be the target of LSALT Peptide (Cell 2019). Arch believes that the drug has the potential to deliver a major breakthrough in the treatment of diseases where inflammation plays a major role.

In 2023 the company has been working on multiple tasks to further advance the LSALT peptide human trials program, including:

Previous Phase II and III human trials during the pandemic accelerated Arch’s drug development plans and shortened the path toward the approval and commercialization of LSALT peptide as a potential treatment for organ inflammation. Inflammation in the lungs was a common complication of hospitalized pandemic patients and LSALT peptide was used for the first time in a Phase II trial to treat acute lung inflammation in that setting. Successful results accelerated LSALT peptide’s inclusion in a national Phase III trial in Canada looking for new treatments to treat acute lung inflammation in the later stages of the pandemic.

ARCH BIOPARTNERS APPROACH

Arch has a long history of working closely with the scientific community, universities and research institutions. The company’s mission is to advance and build the value of select medical innovations, develop the most promising intellectual property, and create value for its investors.

Find out more about LSALT peptide and Arch Biopartners platform of novel therapeutic drugs.

CATALIS Quebec

CATALIS has an extended government mandate aimed at increasing the number of clinical trials carried out by companies in Quebec, promoting excellence in clinical research in Quebec and facilitating collaboration between the various players in the life sciences to accelerate the development of innovative treatments. The CATALIS initiative is funded by the Government of Quebec and by industry players in the form of a public-private partnership with a mission of impact on the environment of the life sciences.

Clinical Trials Ontario (CTO)

Clinical Trials Ontario is an independent not-for-profit organization supported by the Government of Ontario through the Ministry of Research and Innovation. Our vision is to make Ontario a preferred location for global clinical trials by providing the life sciences industry with a streamlined approach to conducting multi-centred clinical trials while ensuring the highest ethical standards for participant safety.